Recommendation for use of diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate, and hepatitis B vaccine in infants

Hye-Kyung Cho; Su Eun Park; Yae-Jean Kim; Dae Sun Jo; Yun-Kyung Kim; Byung-Wook Eun; Taek-Jin Lee; Jina Lee; Hyunju Lee; Ki Hwan Kim; Eun Young Cho; Jong Gyun Ahn; Eun Hwa Choi; Committee on Infectious Diseases of the Korean Pediatric Society

doi:10.3345/cep.2021.00507

Recommendation for use of diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate, and hepatitis B vaccine in infants

Clin Exp Pediatr. 2021 Dec;64(12):602-607. doi: 10.3345/cep.2021.00507. Epub 2021 Jun 8.

Authors

Affiliations

¹ Department of Pediatrics, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
² Department of Pediatrics, School of Medicine, Pusan National University, Pusan, Korea.
³ Department of Pediatrics, Sungkyunkwan University School of Medicine, Suwon, Korea.
⁴ Department of Pediatrics, Jeonbuk National University Medical School, Jeonju, Korea.
⁵ Department of Pediatrics, Korea University College of Medicine, Seoul, Korea.
⁶ Department of Pediatrics, School of Medicine, Eulji University, Daejeon, Korea.
⁷ Department of Pediatrics, CHA University School of Medicine, Pocheon, Korea.
⁸ Department of Pediatrics, University of Ulsan College of Medicine, Ulsan, Korea.
⁹ Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.
¹⁰ Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea.
¹¹ Department of Pediatrics, Chungnam National University School of Medicine, Daejeon, Korea.
¹² Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Korea.

Abstract

In April 2020, the Ministry of Food and Drug Safety licensed a hexavalent combined diphtheria and tetanus toxoids and acellular pertussis (DTaP), inactivated poliovirus (IPV), Haemophilus influenzae type b (Hib) conjugated to tetanus protein, and hepatitis B (HepB) (recombinant DNA) vaccine, DTaP-IPV-Hib-HepB (Hexaxim, Sanofi Pasteur), for use as a 3-dose primary series in infants aged 2, 4, and 6 months. The DTaP-IPV-Hib-HepB vaccine is highly immunogenic and safe and provides a long-term immune response based on studies performed in a variety of settings in many countries, including Korea. This report summarizes the Committee on Infectious Diseases of the Korean Pediatric Society guidelines for the use of this newly introduced hexavalent combination vaccine.

Keywords: Combined; Diphtheria-tetanus-acellular pertussis-inactivate; Infant; Vaccines.